Respiratory microbiota resistance and resilience to pulmonary exacerbation and subsequent antimicrobial intervention by Cuthbertson, Leah et al.
 
 
Respiratory microbiota resistance and resilience to
pulmonary exacerbation and subsequent
antimicrobial intervention
Cuthbertson, Leah; Rogers, Geraint B.; Walker, Alan W.; Oliver, Anna; Green, Laura; Daniels,
Thomas W. V.; Carroll, Mary P.; Parkhill, Julian; Bruce, Kenneth D.; van der Gast,
Christopher J.
DOI:
10.1038/ismej.2015.198
License:
Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Cuthbertson, L, Rogers, GB, Walker, AW, Oliver, A, Green, LE, Daniels, TWV, Carroll, MP, Parkhill, J, Bruce,
KD & van der Gast, CJ 2016, 'Respiratory microbiota resistance and resilience to pulmonary exacerbation and
subsequent antimicrobial intervention', The ISME Journal, vol. 10, no. 5, pp. 1081-1091.
https://doi.org/10.1038/ismej.2015.198
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Checked for eligibility: 15/11/2018
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Feb. 2019
OPEN
ORIGINAL ARTICLE
Respiratory microbiota resistance and resilience to
pulmonary exacerbation and subsequent
antimicrobial intervention
Leah Cuthbertson1,2, Geraint B Rogers3, Alan W Walker4,5, Anna Oliver1, Laura E Green6,
Thomas WV Daniels7, Mary P Carroll7, Julian Parkhill4, Kenneth D Bruce2
and Christopher J van der Gast1
1NERC Centre for Ecology & Hydrology, Wallingford, UK; 2Institute of Pharmaceutical Science, Molecular
Microbiology Research Laboratory, King‘s College London, London SE1 9NH, UK; 3SAHMRI Infection and
Immunity Theme, School of Medicine, Flinders University, Adelaide, South Australia, Australia; 4Pathogen
Genomics Group, Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK; 5Microbiology Group, Rowett
Institute of Nutrition and Health, University of Aberdeen, Aberdeen, UK; 6School of Life Sciences, University
of Warwick, Coventry, UK and 7Cystic Fibrosis Unit, Southampton University Hospitals NHS Trust,
Southampton, UK
Pulmonary symptoms in cystic fibrosis (CF) begin in early life with chronic lung infections and
concomitant airway inflammation leading to progressive loss of lung function. Gradual pulmonary
function decline is interspersed with periods of acute worsening of respiratory symptoms known as
CF pulmonary exacerbations (CFPEs). Cumulatively, CFPEs are associated with more rapid disease
progression. In this study multiple sputum samples were collected from adult CF patients over the
course of CFPEs to better understand how changes in microbiota are associated with CFPE onset
and management. Data were divided into five clinical periods: pre-CFPE baseline, CFPE, antibiotic
treatment, recovery, and post-CFPE baseline. Samples were treated with propidium monoazide prior
to DNA extraction, to remove the impact of bacterial cell death artefacts following antibiotic treatment,
and then characterised by 16S rRNA gene-targeted high-throughput sequencing. Partitioning CF
microbiota into core and rare groups revealed compositional resistance to CFPE and resilience to
antibiotics interventions. Mixed effects modelling of core microbiota members revealed no significant
negative impact on the relative abundance of Pseudomonas aeruginosa across the exacerbation
cycle. Our findings have implications for current CFPE management strategies, supporting
reassessment of existing antimicrobial treatment regimens, as antimicrobial resistance by pathogens
and other members of the microbiota may be significant contributing factors.
The ISME Journal (2016) 10, 1081–1091; doi:10.1038/ismej.2015.198; published online 10 November 2015
Introduction
Cystic fibrosis (CF) is a common recessive genetic
disorder, primarily of Caucasians, affecting more
than 8000 children and adults in the UK and an
estimated 100 000 globally (Davies et al., 2014).
Although this disorder is multisystemic, the leading
cause of morbidity and mortality in an overwhelm-
ing majority (ca. 90%) of patients is chronic lung
infections and concomitant airway inflammation
(Foweraker, 2009). Until a treatment for the disorder
can be found, for example, cystic fibrosis transmem-
brane conductance regulator gene therapy or therapies
that improve cystic fibrosis transmembrane conduc-
tance regulator function, the best way to continue to
raise life expectancy is to improve treatment of the
chronic polymicrobial lung infections (LiPuma, 2014).
Implicit within the aim of improving and directing
treatment is to better understand the nature of those
chronic polymicrobial infections, their response to
standard treatments, and how they differ and change
with disease progression.
Pulmonary symptoms in CF begin in early life and
over time a combination of impaired mucociliary
clearance, innate immune responses, and chronic
infection lead to a progressive loss of lung function
(Flume et al., 2009). This gradual decline in
pulmonary function is interspersed with periods of
acute worsening of respiratory symptoms known as CF
pulmonary exacerbations (CFPEs) (Sibley et al., 2008).
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Cumulatively, these periods of CFPE are associated
with more rapid disease progression and reduced
survival as well as a recognised reduction in quality
of life and an increase in overall healthcare costs
(VanDevanter et al., 2013). There is currently no
consensus for a generally applicable definition to
describe when patients are experiencing a CFPE.
This is mainly due to a lack of consistency in the
symptoms experienced by CF patients of different
ages and disease state, thus making it challenging for
paediatric and adult physicians to come to an
agreement (Smyth and Elborn, 2008). Despite this,
clinical features can include decreased exercise
tolerance, increased cough and sputum production,
shortness of breath, chest pain, absence from school
or work, increased adventitial sounds on lung
examination, decreased appetite or weight loss, and
a decline in lung function (Fuchs et al., 1994).
Although lung function is still widely relied upon as
an indicator of worsening symptoms, it has been
revealed that short-term changes in lung function
show little effect on the sensitivity or specificity of
CFPE diagnosis (Rosenfeld et al., 2001).
As such, clinicians face the challenging role of
determining if a patient is experiencing a CFPE and
hence when intervention is appropriate. CFPEs are
treated with high-dose intravenous antibiotics that
are broad spectrum in their activity, but expected to
have an impact on Pseudomonas aeruginosa (Smyth
and Elborn, 2008). It is now recognised that
immediate management of CFPE results in improved
prognosis and increased likelihood of patient
recovery, underlining the importance of CFPE
diagnosis (Sanders et al., 2010). Therefore, there is
an urgent need to identify and develop more reliable
bioindicators of disease state change.
Studies using ecological analyses to aid in the
interpretation of culture, independent data have
shown associations between respiratory microbiota
characteristics and clinical outcomes (LiPuma, 2014).
For example, increasing age, disease progression,
and reduced lung function have been associated with
related changes in CF lung microbiota, summarised
in reduced bacterial diversity and increasingly con-
served community composition (e.g. Cox et al., 2010;
Klepac-Ceraj et al., 2010; van der Gast et al., 2011;
Zhao et al., 2012; van der Gast et al., 2014). However,
a fundamental knowledge gap remains in relation to
how the CF microbiota behaves and respond to CFPE
and subsequent antibiotic interventions, largely due to
a paucity of studies on this subject.
A useful framework proposed to better understand
changes in microbiota associated with CFPE and
antibiotic intervention has been to partition data into
defined clinical periods: (B) baseline, (E) CFPE, (T)
treatment, and (R) recovery (Zhao et al., 2012; Price
et al., 2013). Set within this BETR classification,
studies have provided useful insights including a
clear demonstration that CFPE do not result from
increased total bacterial density or density of
a specific recognised CF pathogen, such as
P. aeruginosa (Stressmann et al., 2011; Fodor et al.,
2012; Carmody et al., 2013; Price et al., 2013).
Conversely, how changes in microbiota composition
and structure are associated with CFPE and interven-
tion remain less clear; as different studies have shown
either significant change or no change in CF bacterial
communities, and in specific constituent species
(Fodor et al., 2012; Stressmann et al., 2012; Daniels
et al., 2013; Price et al., 2013; Smith et al., 2014).
These contradictory findings may be attributed to
differing experimental designs, patient cohorts, and
sampling strategies. For example, studies have typi-
cally relied on single-point samples to be representa-
tive of a given disease state (e.g. baseline or
exacerbation) which will not account for variance in
either microbiota or clinical factors, such as lung
function (commonly, FEV1, forced expiratory volume
in 1 s), in a given clinical period (Carmody et al., 2013;
Price et al., 2013; Zemanick et al., 2013). Studies have
also been based in the main on point samples from
subsets and different combinations of the clinical
periods defined above (Fodor et al., 2012; Carmody
et al., 2013; Price et al., 2013; Smith et al., 2014),
making them difficult to compare, and as such the
complete cycle of clinical periods from pre- to post-
CFPE baseline, that is BETRB, has not been studied.
However, in both instances this may be a reflection
of the difficulty in obtaining respiratory samples and
metadata over this type of longitudinal period.
In the current study, multiple sputum samples
were collected from 10 CF adult patients over the
course of a CFPE. The data were partitioned into five
clinical periods: (B0) baseline pre-CFPE; (E) CFPE,
30 days prior to treatment; (T) treatment for CFPE;
(R) recovery, 30 days post-CFPE; and (B1) baseline
post-CFPE. In addition, multiple sputum samples
were collected from two adult CF patients who were
clinically stable over the same time period (B0 only).
During periods B0, E, R, and B1, patients were
receiving their standard doses of maintenance anti-
biotics. For T, patients were hospitalised and
receiving increased antibiotic intervention, which
was typically intravenous antibiotics (Table 1). To
allow profiling of the extant CF lung microbiota,
sputum samples were treated with propidium mono-
azide prior to DNA extraction, to remove the impact
of extracellular DNA or DNA from dead or damaged
bacterial cells, and then 16S rRNA gene-targeted
high-throughput sequencing was carried out (Rogers
et al., 2013). This allowed a detailed examination of
(1) how changes in CF microbiota are associated with
the onset of CFPEs, (2) the effect of antibiotic therapy
administered for treatment of CFPE on the CF
microbiota, and (3) identification of potential bio-
markers of disease state change.
Materials and methods
Patients and clinical samples
This study was undertaken with the local ethical
approval from Southampton and South West
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Hampshire Research Ethics Committee (06/Q1704/24).
Sputum samples were collected from 12 adult CF
patients attending the Southampton General
Hospital, Southampton, UK (Table 1). All sputum
samples were stored at 4oC immediately after
expectoration and transferred to − 80 °C storage
within 12 h of expectoration. This timeframe was
selected as recent evidence suggests that failure to
stabilise samples at − 80 °C within 12 h significantly
impacts sequence-based microbiota profiling.
(Cuthbertson et al., 2014). Subjects were selected
due to their persistent production of sputum and
history of CFPE. All patients were clinically defined
as chronically colonised with P. aeruginosa. Sam-
ples were collected from patients during periods of
baseline, defined as periods where patients were
only receiving maintenance doses of antibiotics.
During the study period 10 of the 12 patients were
treated for a CFPE. The start and end of CFPE were
identified by treating clinicians, and were defined
for the purpose of this study as the period of time
where patients received clinical intervention in
the form of antibiotic treatment. The antibiotics
administered to each patient are all broad spectrum
in activity and are expected to have an impact on the
predominant pathogen, P. aeruginosa (Table 1).
Decisions to initiate treatment were based on
worsening clinical symptoms (Fuchs et al., 1994).
Stabilisation or improvement of these symptoms led
to the termination of this treatment. Retrospectively
samples were partitioned into five periods: (B0)
baseline pre-CFPE; (E) CFPE, within 30 days prior
to antibiotic treatment; (T) period of time patients
were receiving treatment for pulmonary exacerba-
tion; (R) recovery, within 30 days post-treatment for
CFPE; and (B1) baseline post-CFPE. Clinically
relevant symptoms were monitored throughout the
sampling period. Lung function (FEV1) was assessed
using a Koko PeakPro home spirometer (Ferraris
Cardiorespiratory, Louisville, CO, USA) at the time
of each sample collection. Patients were also
required to assess respiratory symptoms: cough,
breathlessness, sputum production, and general
wellbeing, using a visual analogue scale scored
0–100, with 0 being the worst and 100 the best.
DNA extraction and pyrosequencing
Sputum samples were washed three times with
1× phosphate-buffered saline to remove saliva as
previously described (Rogers et al., 2006). Extracellular
DNA and DNA from nonviable cells were excluded
from analysis via cross-linking with propidium
monoazide prior to DNA extraction, as previously
described (Rogers et al., 2013). Barcode encoded FLX
amplicon pyrosequencing was performed using the
primer 338F (5′-ACTCCTACGGGAGGCAGCAG) and
926R (5′-CCGTCAATTCMTTTRAGT) as described
previously (Cooper et al., 2013). Except, initial
generation of 16S rRNA gene amplicons involved a
one-step polymerase chain reaction of 25 cycles
using AccuPrime Taq DNA Polymerase High Fidelity
(Invitrogen, Carlsbad, CA, USA). polymerase chain
reaction-negative controls were included in each
sequencing run (Salter et al., 2014). Four hundred
and fifty-four pyrosequencing using the Lib-L kit was
performed at the Wellcome Trust Sanger Institute
(Hinxton, UK).
Sequence analysis
The mothur sequencing analysis platform was used
to analyse the resulting data (Schloss et al., 2011).
Sequence quality was ensured by trimming reads
where the average quality score fell below 35 across
a rolling window of 50 bases. Reads shorter than
400 bp in length and those that included mismatches
in the barcode or 16S rRNA gene primer sequence,
ambiguous base calls and homopolymeric stretches
longer than 8 bases were subsequently removed.
Chimeras were removed in mothur using the Perseus
software program (Quince et al., 2011). Sequences
were assembled into operational taxonomic units
(OTUs) at 97% sequence identity to give an
Table 1 Summary of clinical characteristics for individual patients
Patient Age (years) Gender CFTR genotype BMI CF diabetes CFPE antibioticsa
1 30 Male ΔF508/NK 29 No Ciprofloxacin p.o.
2 45 Female ΔF508/NK 18.2 Yes Colomycin i.v.+Tobramycin i.v.
3 47 Male ΔF508/NK 19.9 Yes
4 22 Female ΔF508/ΔF508 18 No Cirprofloxacin p.o., then, Meropenem i.v.+Amakacin i.v.
5 55 Male ΔF508/G58E 23.9 No Ceftazidime i.v.+Gentamicin i.v.
6 21 Female ΔF508/ΔF508 20.3 No Ciprofloxacin p.o.
7 40 Male ΔF508/ΔF508 19.4 Yes
8 22 Male ΔF508/ΔF508 18.4 Yes Meropenem i.v.+Colomycin i.v.
9 17 Female ΔF508/ΔF508 22.5 No Ceftazidime i.v.+Gentamicin i.v.
10 24 Female ΔF508/G542X 21 No Clarithromycin p.o.
11 20 Male ΔF508/ΔF508 20.4 No Ciprofloxacin p.o.+Metronidazole
12 20 Male ΔF508/ΔF508 28.5 No Ceftazidime i.v.+Gentamicin i.v.
Abbreviations: BMI, body mass index (kgm2); CFTR, cystic fibrosis transmembrane conductance regulator; NK, genotype not known (the clinical
and functional translation of CFTR (CFTR2); http://cftr2.org).
aAntibiotics administered as intervention for a clinically defined CFPE: p.o., oral; i.v., intravenous.
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approximation of species (Schloss and Handelsman,
2006) and identified using the Ribosomal Database
Project reference database provided in mothur.
OTUs identified in negative controls were removed
from further analysis (Salter et al., 2014).
As the Ribosomal Database Project classifier only
provides classifications down to the genus level,
representative sequences from each OTU were used
to give appropriate species-level identifications
using MegaBlast against the NCBI nucleotide
archive. For some OTUs multiple, equally scoring,
matches were obtained, As such, species-level
designations should be considered putative. The
raw sequence data reported in this study have
been deposited in the European Nucleotide Archive
under study accession numbers ERP005251 and
ERP007059, and sample accession numbers
ERS421603 and ERS551400. The relevant barcode
information for each sample is shown in
Supplementary Table S1.
Statistical analysis
Species were partitioned into core and rare species
groups using a modification of the method pre-
viously described (van der Gast et al., 2011). Based
on a significant positive distribution–abundance
relationship, the persistent and abundant core
species were defined as those in more than 75% of
all samples, while all other species falling outside of
the upper quartile were considered to be rare (Hedin
et al., 2015). Species turnover between consecutive
samples was measured using the method described
by Brown and Kodric-Brown (1977). Turnover was
defined as t= b+c/S1+S2. Where b= the number of
species present only in the first sample; c= the
number of species present only in the second
sample; S1 = the total number of species in the first
sample; and S2 the total number of species in the
second sample (Brown and Kodric-Brown, 1977).
Species richness (S*) was used as previously
described (Rogers et al., 2013). In brief, S* was
calculated with a uniform re-sample size (to match
the smallest sequence size in each group) following
1000 iterations in each instance and performed
in R version 3.1.1 (Oksanen et al., 2013; The R
Development Core Team, 2013). Two sample t-tests,
regression analysis, coefficients of determination (r2),
residuals and significance (P) were calculated using
Minitab software (version 16; Minitab, University
Park, PA, UK). Analysis of similarity (ANOSIM) and
similarity of percentages analysis (SIMPER) were
performed using the PAST (Paleontological Statis-
tics, version 3.01) program available from the
University of Oslo (http://folk.uio.no/ohammer/past).
The Bray–Curtis quantitative index of similarity was
used as the underpinning community similarity
measure for both ANOSIM and SIMPER analyses.
Mixed-effect models were fitted in R version 3.1.1
using the GLMMADMB package version 0.8.0
(The R Development Core Team, 2013). Values of
r2 were calculated using the R package MuMIN. To
analyse species-level changes over the disease
periods, mixed-effect models (GLMMADMB) with
negative bionomial errors were used as data were
over dispersed (greater variability than would be
expected based on Poisson distribution). For each
species, the change in abundance across all patients
was measured using the disease period as the fixed
effect and variation between patients was accounted
for by including patient as a random effect. The
model fits changes in abundance on the logit
scale. The null hypothesis for each species was
there would be no change in species abundance
between periods.
Results
An expectation for patterns of lung function (FEV1)
within individual patients was that it would entail a
consistent decline in FEV1 from baseline (B0) through
the CFPE and into the treatment periods, followed
by an improvement in the subsequent periods.
However, no common pattern in lung function by
clinical period was observed across the 10 patients
that experienced CFPE (Supplementary Figure S1).
Therefore, within the current study, FEV1 was found
to be a poor indicator of short-term disease state.
Microbiota diversity and composition from
respiratory samples was assessed using 16S rRNA
gene-targeted pyrosequencing. From 237 samples, a
total of 386 002 bacterial sequence reads (mean ±
standard deviation (s.d.) per sample, 1628± 84) were
included in the final analysis, identifying 103 genera
and 183 distinct OTUs classified to the species level
(Supplementary Table S2); however, given the
relative length of the ribosomal sequences analysed,
these identities should be considered putative.
The average numbers of bacterial sequence reads
per sample were similar among the five disease
states: (B0) n=56, 1845±247 (mean ± s.d.); (E) n=41,
1357±136; (T) n=67, 1643±127; (R) n=32, 1845±151;
and (B1) n=41, 1449±212 (Supplementary Table S3).
We have previously established that categorisation
of component species in CF microbiota into core and
rare species revealed important aspects of species-
abundance distributions with a metacommunity
that would be neglected without such a distinction
(van der Gast et al., 2011, 2014). A coherent
metacommunity could be expected to exhibit a
direct relationship between prevalence and propor-
tional abundance of individual species within the
constituent communities. Consistent with this
prediction, the abundance of OTUs, across all
samples and within specific disease periods
(Figure 1), was significantly correlated with the
number of individual respiratory sample commu-
nities that those OTUs occupied. On that basis, OTUs
present in more than 75% of all samples, and
hence highly abundant, were classified as core
(Hedin et al., 2015). These were derived from five
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common taxa, P. aeruginosa, Streptococcus pneumoniae
group, Streptococcus sanguinis group, Prevotella
melaninogenica/veroralis/histicola (abbreviated here-
after as P. melaninogenica), and Veillonella parvula/
rogosae (abbreviated as P. parvula), and accounted
for over 84% of the total sequence abundance.
Conversely, the rare OTU group accounted for the
majority of the diversity, 178 OTUs.
The rate of species turnover, the number of OTUs
eliminated and replaced over time, was assessed for
each patient over the study period (Figure 2). The
rate of OTU turnover showed more variation in the
periods surrounding and during treatment for
CFPE. Whereas pre- and post-baseline periods had
relatively consistent OTU turnover rates, particularly
evident for patients 3 and 7 who did not experience a
CFPE over the course of the study (Figure 2). The rate
of turnover in the rare microbiota group was greater
and more variable than that observed for the core
microbiota group, suggesting that the more diverse
rare microbiota was driving the observed changes in
the whole microbiota. Species richness (S*) within
the whole microbiota increased significantly from
baseline (B0) within the CFPE and treatment periods,
returning to B0 levels in the subsequent recovery and
post-CFPE baseline (B1) periods. Again, these
patterns of diversity were driven by changes within
the rare microbiota (Figure 3). Diversity within the
core microbiota significantly decreased within the
treatment period, with Prevotella melaninogenica
and Veillonella parvula moving into the rare group
for that period (Figures 1 and 3).
ANOSIM, using the Bray–Curtis quantitative index
of similarity, was used to determine how composi-
tion within the whole, core, and rare microbiota
changed by disease period (Table 2). No significant
change was observed between disease periods
within the whole microbiota. Conversely, significant
differences within the core microbiota were observed
between pre-CFPE baseline and treatment periods
(Table 2). Additionally, significant differences
within the rare microbiota were observed between
pre-CFPE baseline and the treatment and recovery
periods. No significant compositional differences
were observed between pre- and post-CFPE baseline
periods for both the core and rare OTU groups
(Table 2). The switching of the two core OTUs,
P. melaninogenica and Veillonella parvula, to the
rare group in the treatment period will have likely
contributed to the significant differences for the core
and rare microbiota between pre-CFPE baseline and
treatment periods but not for the whole microbiota,
where group membership is not accounted for.
SIMPER analysis was employed to assess the
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contribution of individual OTUs to differences in
similarity within the whole microbiota, core, and
rare OTU groups between disease periods
(Supplementary Tables S4–S6). P. aeruginosa,
followed by S. pneumoniae group, contributed most
to dissimilarity in the whole microbiota and core OTU
group between all disease periods (Supplementary
Tables S4 and S5). Within the rare OTU group,
Porphyromonas catoniae was observed to provide
the greatest contribution to dissimilarity between all
disease periods, with the exception of the compar-
ison between the CFPE treatment and recovery
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periods, where V. parvula provided the largest
contribution.
SIMPER analysis also revealed changes in the
percentage contribution of individual OTUs within
the core microbiota by disease period. Mixed effects
models were used to further investigate how indivi-
dual core OTUs changed between disease periods
(Figure 4). P. catoniae, the most abundant of the
rare OTU group, was also included in this analysis.
These models allowed for the inclusion of both fixed
(disease period) and random effects (patient), and
therefore variation between patients was accounted
for in each model. For P. aeruginosa, no significant
change in relative abundance from pre-CFPE
baseline (B0) was observed in the CFPE and
treatment periods. However, a significant increase
in proportional abundance was observed within the
recovery period returning to B0 abundance levels in
the post-CFPE baseline period (B1). No significant
changes in relative abundance from B0 were
observed for the S. pneumoniae group OTU in any
of the disease periods. S. sanguinis group and
P. catoniae both had significantly reduced abundance
within the treatment period, with the former OTU
also significantly lower in the recovery period.
P. melaninogenica proportional abundance signifi-
cantly reduced from baseline (B0) over the CFPE,
treatment, and recovery periods before returning
to pre-CFPE baseline (B0) levels in period B1.
Conversely, the proportional abundance of V. parvula
significantly increased over the same periods
(Figure 4).
Discussion
Cross-sectional studies have informed our under-
standing of CF chronic lung infections, revealing a
complex and highly variable microbiota in a con-
stantly perturbed ecosystem (van der Gast et al.,
2011, 2014). However, in order to better understand
the progressive nature of chronic lung infection in
CF, it is important to investigate how the bacterial
communities change through time in relation to
disease state and progression. A small number of
studies have attempted to understand bacterial
community dynamics within the CF lung (Stressmann
et al., 2012; Zhao et al., 2012; Carmody et al., 2013;
Price et al., 2013). A common limitation, as stated by
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Figure 3 Changes in metacommunity diversity across the disease
periods. Given are the whole microbiota, core and rare OTUs
groups. Disease periods are denoted by (B0) baseline pre-CFPE;
(E) CFPE, 30 days prior to treatment; (T) treatment for clinical
exacerbation; (R) recovery, 30 days post-CFPE treatment; and (B1)
baseline post-CFPE. Richness (S*) was calculated with a uniform
re-sample size following 1000 iterations in each instance;
re-sample sizes by group were n=55 656 (whole), n=47 092
(core), and n=8712 (rare) equating to the lowest number of
sequences by disease period within each group. Error bars
represent the standard deviation of the mean. Asterisks denote
significant differences between B0 and subsequent disease periods
at the Po0.05 level and determined by two sample t-tests.
Table 2 Analysis of similarities (ANOSIM) of whole, common,
and rare microbiota between disease periods
B0 E T R B1
Whole
B0 — 0.210 0.092 0.413 0.562
E 0.012 — 0.276 0.177 0.342
T 0.019 0.012 — 0.778 0.396
R 0.001 0.017 −0.034 — 0.199
B1 −0.007 0.001 0.003 0.014 —
Common
B0 — 0.197 0.01* 0.477 0.533
E 0.011 — 0.04* 0.208 0.488
T 0.145 0.157 — 0.518 0.152
R −0.005 0.013 −0.008 — 0.140
B1 −0.006 −0.004 0.029 0.022 —
Rare
B0 — 0.123 0.0001* 0.017* 0.574
E 0.027 — 0.0002* 0.024* 0.005*
T 0.195 0.152 — 0.0002* 0.0001*
R 0.194 0.156 0.206 — 0.008*
B1 −0.007 0.149 0.194 0.071 —
ANOSIM test statistic (R) and probability (P) that two compared
groups are significantly different at the Po0.05 level (denoted with
asterisks) are given in the lower and upper triangles, respectively.
ANOSIM R and P values were generated using the Bray–Curtis
measure of similarity. Disease states are denoted by (B0) stable
pre-CFPE; (E) CFPE, 30 days prior to CFPE treatment; (T) treatment for
clinical exacerbation; (R) 30 days post-CFPE treatment; and (B1) stable
post-CFPE.
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Carmody and colleagues (2013) for their own study,
has been narrow frequency of sampling, which
would not allow fluctuations in airway microbiota
to be accounted for, within or between clinical
periods. Indeed this within clinical period fluctua-
tion was particularly highlighted in the current
study, where species turnover was more variable in
the CFPE, treatment, and recovery periods (Figure 2).
By collecting samples and associated metadata at
more frequent intervals the current study was able to
not only account for variation within the microbiota
over time but also investigate how this related to
changes in disease state through the full cycle of an
exacerbation event.
Resistance can be defined as ‘the degree to which
microbial composition remains unchanged in the
face of a disturbance’ and resilience as ‘the rate at
which microbial composition returns to its original
composition after being disturbed’ regardless of the
system studied (Allison and Martiny, 2008). Pre-
viously, Price et al. (2013) and Stressmann et al.
(2011) reported no significant change in community
composition through CFPE and treatment. Congruent
with those studies we found that the whole
microbiota did not significantly change in composi-
tion across the five clinical periods studied, indicat-
ing resistance to perturbations within the lung
(Table 2). However, partitioning the whole chronic
lung infection microbiota revealed there was resi-
lience to intervention with antibiotics within both
the core and rare OTU groups (Table 2), a pattern
also reflected within the diversity based analysis
(Figure 3).
Infection with P. aeruginosa has been highlighted
as a key factor in poor clinical outcomes and is
typically one of the main targets for treatment. It was
therefore surprising that its proportional abundance
remained high across all clinical periods, even
exhibiting a significant increase in abundance in
the recovery period (Figure 4). While the relative
abundance from high-throughput sequencing data of
a given species may not be considered strictly
quantitative, Price et al. (2013) demonstrated a
highly significant correlation between the results of
P. aeruginosa-targeted quantitative polymerase
chain reaction and sequencing data. One possible
explanation for the increase in P. aeruginosa propor-
tional abundances observed after the conclusion of
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Figure 4 Trends in the relative abundance of bacterial species with change in disease period. Parameters are extracted from mixed-effects
models based on 237 samples from 12 patients. (B0) baseline pre-CFPE, (E) CFPE, 30 days prior to antibiotic treatment, (T) period of time
patients were receiving treatment for pulmonary exacerbation, (R) recovery, 30 days post-treatment, (B1) baseline post-CFPE. **Po0.001,
*Po0.05. ‡ indicates rare group membership.
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treatment is that antibiotic therapy led to a reduction
in the abundance of other species, thereby allowing
P. aeruginosa to take advantage of newly available
physical niche space. Even so, the proportional
abundance of P. aeruginosa returned to baseline
after the 30-day post-treatment recovery period,
which may be due to the resilience of the members
of the rare species group.
The lack of a generally applicable definition of
CFPE and a robust general marker of disease state
represents a major challenge for the timely treatment
of exacerbations. As stated by Rosenfeld et al. (2001)
and confirmed from the FEV1 data (Supplementary
Figure S1), changes in lung function demonstrates
little sensitivity or specificity of CFPE diagnosis.
Molecular diagnostic tests are being increasingly
employed in diagnosis of infectious diseases, allow-
ing disease-associated biomarkers to be used to
identify, predict, and monitor changes in infections
(Pattison et al., 2013). The identification of biomar-
kers in CF could potentially provide important tools
to improve CFPE identification and therefore
improve outcomes for CF patients. Within the
current study, Veillonella species related to
V. parvula/rogosae and Prevotella species related to
P. melaninogenica/veroralis/histicola represent poten-
tial biomarkers of disease state due to their significant
changes in abundance from baseline prior to the start
of antibiotic treatment (Figure 4). Development of
targeted quantitative polymerase chain reaction
based analysis is required to test the efficacy of
these two OTUs as molecular diagnostic tools for the
onset of CFPE.
While our study was limited to a detailed
examination of a relatively small number of patients,
our findings have relevance to current management
strategies for CFPEs. CF patients receive frequent and
prolonged courses of antibiotics, often at high doses,
especially for CFPE treatment. Smyth and Elborn
(2008) stated there is no comparable medical condi-
tion where so many individuals are exposed to
antibiotics and risk of cumulative antibiotic side
effects in this way. While the resilience within the
core and rare species groups will be of concern with
regard to treatment, of particular interest to
clinicians will be the lack of substantial negative
impact on P. aeruginosa. Antibiotics administered in
response to the worsening symptoms associated with
CFPE are expected to target P. aeruginosa, which is
the emblematic species of chronic lung infections in
CF patients. Antimicrobial resistance by recognised
respiratory pathogens and other members of the
microbiota may be a significant contributing factor
underpinning the findings of this study (Sherrard
et al., 2014). Therefore this study strongly highlights
the merits of continual reassessment of existing
antimicrobial treatment regimens and antibiotic
delivery strategies (Sherrard et al., 2014).
From a more fundamental perspective, the com-
position of the bacterial microbiota is most likely not
the whole story. At the population level, studies
have shown a variety of co-infection interactions
between P. aeruginosa and other co-colonizing
microbes, increasing the virulence of this core CF
pathogen. For example, P. aeruginosa can use
peptidoglycan shed by Gram-positive bacteria as a
cue for enhanced virulence (Korgaonkar et al., 2013),
metabolites are transferred (e.g. 2,3-butanediol)
between fermenting bacteria and P. aeruginosa
(Venkataraman et al., 2014; Whiteson et al., 2014),
and, similarly, ethanol produced by the fungus
Candida albicans can influence P. aeruginosa
biofilm formation and phenazine production (Chen
et al., 2014). Therefore the wider microbial commu-
nity and the myriad of interactions therein need to be
considered through, for example, metagenomic,
metatranscriptomic, and metabolomic approaches
to elucidate the roles of bacteria, fungi, and respira-
tory viruses in tandem, alongside host immune
responses. Studies of this nature could reveal the
underlying cause or causes of CFPE and it may well
be the case that there is no consistent factor
(infection or host) that trigger exacerbations, either
within or between patients.
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